Published in J Alzheimers Dis on January 01, 2011
Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet (2012) 1.04
Brain-specific knockdown of miR-29 results in neuronal cell death and ataxia in mice. RNA (2014) 0.93
Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease? Biochim Biophys Acta (2012) 0.92
VDAC proteomics: post-translation modifications. Biochim Biophys Acta (2011) 0.90
Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage. Biochim Biophys Acta (2013) 0.84
The regulation of apoptosis by the downstream regulatory element antagonist modulator/potassium channel interacting protein 3 (DREAM/KChIP3) through interactions with hexokinase I. Biochem Biophys Res Commun (2013) 0.81
The Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy. J Biol Chem (2015) 0.81
Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction. J Biol Chem (2016) 0.80
Proteomic analysis of lymphoblastoid cells from Nasu-Hakola patients: a step forward in our understanding of this neurodegenerative disorder. PLoS One (2014) 0.79
Differential proteomic and behavioral effects of long-term voluntary exercise in wild-type and APP-overexpressing transgenics. Neurobiol Dis (2015) 0.79
Small-molecule inducers of Aβ-42 peptide production share a common mechanism of action. FASEB J (2012) 0.79
Thermodynamic and structural characterization of an antibody gel. MAbs (2013) 0.78
Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro. J Biol Chem (2014) 0.77
From a Cell's Viewpoint: Targeting Mitochondria in Alzheimer's disease. Drug Discov Today Ther Strateg (2013) 0.75
Mitochondrial VDAC1: A Key Gatekeeper as Potential Therapeutic Target. Front Physiol (2017) 0.75
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology (2009) 1.84
Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology (2007) 1.64
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Effects of neonatal stress on markers of synaptic plasticity in the hippocampus: implications for spatial memory. Hippocampus (2009) 1.22
Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun (2008) 1.15
Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. Neurobiol Dis (2008) 1.13
Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology (2010) 1.12
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis (2005) 1.11
Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology (2002) 1.09
Interactions between age, stress and insulin on cognition: implications for Alzheimer's disease. Neuropsychopharmacology (2010) 1.04
Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem Biophys Res Commun (2006) 1.01
Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol Aging (2005) 0.99
Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology (2005) 0.96
Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice. J Alzheimers Dis (2012) 0.95
Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate. J Biol Chem (2003) 0.95
Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: involvement of the HPA axis. Psychoneuroendocrinology (2009) 0.91
Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease. FASEB J (2012) 0.89
Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus. Brain Res Mol Brain Res (2004) 0.87
2-Oxopiperazine-based gamma-turn conformationally constrained peptides: synthesis of CCK-4 analogues. J Org Chem (2002) 0.85
GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells. Hippocampus (2014) 0.84
Differential effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on BDNF mRNA expression in rat frontal cortex and hippocampus. Neurosci Lett (2006) 0.84
Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation. Behav Brain Res (2011) 0.83
Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors. J Med Chem (2002) 0.83
Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors. Eur J Pharmacol (2002) 0.83
Serotonin 5-HT receptor blockade enhances Ca(2+)/calmodulin-dependent protein kinase II function and membrane expression of AMPA receptor subunits in the rat hippocampus: implications for memory formation. J Neurochem (2005) 0.82
Ischemia induces cell proliferation and neurogenesis in the gerbil hippocampus in response to neuronal death. Neurosci Res (2008) 0.81
GABA(A) receptor antagonists enhance cortical acetylcholine release induced by 5-HT(3) receptor blockade in freely moving rats. Brain Res (2002) 0.80
The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J Neurochem (2009) 0.79
Neuroprotective effects of serotonin 5-HT 1A receptor activation against ischemic cell damage in gerbil hippocampus: Involvement of NMDA receptor NR1 subunit and BDNF. Brain Res (2008) 0.78
Analogues of the neuroprotective tripeptide Gly-Pro-Glu (GPE): synthesis and structure-activity relationships. Bioorg Med Chem Lett (2005) 0.78
[Perspectives on the amyloid cascade hypothesis of Alzheimer's disease]. Rev Neurol (2010) 0.78
Synthesis and biological properties of beta-turned Abeta(31-35) constrained analogues. Bioorg Med Chem Lett (2008) 0.78
New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett (2006) 0.78
Altered expression of neuronal tryptophan hydroxylase-2 mRNA in the dorsal and median raphe nuclei of three genetically modified mouse models relevant to depression and anxiety. J Chem Neuroanat (2011) 0.78
Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.77
Limited Unfolded Protein Response and Inflammation in Neuroserpinopathy. J Neuropathol Exp Neurol (2016) 0.77
Role of hippocampal CaMKII in serotonin 5-HT(1A) receptor-mediated learning deficit in rats. Neuropsychopharmacology (2004) 0.77
The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett (2006) 0.77
Phenyl acyl acids attenuate the unfolded protein response in tunicamycin-treated neuroblastoma cells. PLoS One (2013) 0.75
5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors. J Med Chem (2004) 0.75
Effects of the incorporation of IBTM beta-turn mimetics into the dipeptoid CCK(1) receptor agonist PD 170292. Bioorg Med Chem Lett (2002) 0.75
Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics. J Med Chem (2005) 0.75
New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage. J Med Chem (2011) 0.75
Benzimidazole derivatives. Part 5: design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands. Bioorg Med Chem (2004) 0.75
Involvement of the vascular wall in regenerative processes after CA1 ischemic neuronal death. Int J Dev Neurosci (2008) 0.75
Design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands. Bioorg Med Chem Lett (2003) 0.75